Vaccine against COVID-19 or against SARS-CoV-2 infection?

Piotr Rieske

doi:10.5114/pja.2020.97913

eISSN: 2391-6052
ISSN: 2353-3854

Alergologia Polska - Polish Journal of Allergology

Current issue Archive Manuscripts accepted About the journal Editorial board Abstracting and indexing Subscription Contact Publication charge Supplements Special issues Instructions for authors Publication charge

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Open access

3/2020
vol. 7

Send email

Copy url:

abstract:

Review paper

Vaccine against COVID-19 or against SARS-CoV-2 infection?

Piotr Rieske

^{1, 2}

Zakład Biologii Nowotworów, Uniwersytet Medyczny w Łodzi
Celther Polska

Alergologia Polska – Polish Journal of Allergology 2020; 7, 3: 131–145

DOI: https://doi.org/10.5114/pja.2020.97913

Online publish date: 2020/08/05

View full text Get citation

PlumX metrics:

Article offers analysis of main aspects of SARS-CoV-2/COVID-19 vaccination (severe acute respiratory syndrome coronavirus 2/COVID-19-Coronavirus Disease 2019). Optimal vaccine should protect not only against disease COVID-19 (symptoms), but also against SARS-CoV-2 infection (spreading disease). However, this kind of vaccine – showing highest safety level is extremely difficult to get. Several additional SARS-CoV-2/COVID-19 vaccination issues were addressed in article. For example: serological passports, herd immunity, clinical trials, and role of antibodies and T cells crossreactivities. Article discusses some issues related to vaccination responsibilities.

keywords:

Vaccine against COVID-19 or against SARS-CoV-2 infection?

Piotr Rieske 1, 2

SARS-CoV-2, vaccine, COVID-19

Piotr Rieske

^{1, 2}